Related Experiment Videos

[The use of fluconazole in low-weight neonates with candidiasis]

N Saporito1, L G Tina, P Betta

  • 1Istituto Clinica Pediatrica II, Università di Catania, Italia.

Insights

Systemic Candida Albicans infections in premature newborns require prompt diagnosis and treatment. Fluconazole effectively treated candidiasis in fourteen newborns, with no adverse effects observed.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Mycology

Background:

  • Systemic Candida Albicans infections pose significant morbidity risks in premature infants.
  • Early detection and intervention are critical for improving outcomes in neonatal candidiasis.

Purpose of the Study:

  • To report on the diagnosis and treatment of systemic candidiasis in fourteen premature newborns.
  • To evaluate the efficacy and safety of fluconazole in treating neonatal candidiasis.

Main Methods:

  • Retrospective case series of fourteen newborns diagnosed with candidiasis.
  • Isolation of Candida Albicans from various bodily fluids and sites.
  • Treatment with fluconazole administered parenterally or locally.

Main Results:

  • Candida Albicans was isolated from blood, liquor, peritoneal fluid, urine, and oesophageal aspirates.
  • All fourteen neonates received fluconazole treatment for 5 to 21 days.
  • Complete negativization of cultures was achieved in all treated cases.
  • No systemic or local side effects were reported during fluconazole treatment.

Conclusions:

  • Fluconazole is an effective and safe treatment for systemic Candida Albicans infections in premature newborns.
  • Prompt diagnosis and treatment with fluconazole can lead to favorable outcomes, including complete recovery.

Related Concept Videos